← Back to Search

Proportional Open Ventilation System

Life2000® Ventilator for Coronavirus

N/A
Waitlist Available
Led By Jonathan Shelver, MD
Research Sponsored by Hill-Rom
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Patients who meet all of the following inclusion criteria and no
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up time frame measured will include date that patient is admitted to hospital until date patient is discharged from hospital or death occurs with an anticipated 30 day time period, but shall not exceed 90 day time period.
Awards & highlights

Study Summary

This study is evaluating whether a new ventilator may help reduce the need for invasive mechanical ventilation in individuals with acute respiratory distress syndrome.

Eligible Conditions
  • Acute Respiratory Failure
  • Coronavirus

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~time frame measured will include date that patient is admitted to hospital until date patient is discharged from hospital or death occurs with an anticipated 30 day time period, but shall not exceed 90 day time period.
This trial's timeline: 3 weeks for screening, Varies for treatment, and time frame measured will include date that patient is admitted to hospital until date patient is discharged from hospital or death occurs with an anticipated 30 day time period, but shall not exceed 90 day time period. for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Life2000® Compared to HFNC (AIRVO)
Secondary outcome measures
PEEP level

Trial Design

2Treatment groups
Experimental Treatment
Active Control
Group I: Life2000® VentilatorExperimental Treatment1 Intervention
Subjects in the active treatment group will receive ventilatory support with Life2000® Ventilator following the labeled instructions for the device.
Group II: Control GroupActive Control1 Intervention
Subjects in the control group will be identified from the population of patients previously admitted to the study site with COVID-19 infection who required non-invasive oxygen therapy with HFNC but were not treated with NIV therapy. Subject data will be collected retrospectively from the medical record.

Find a Location

Who is running the clinical trial?

Hill-RomLead Sponsor
33 Previous Clinical Trials
2,859 Total Patients Enrolled
Jonathan Shelver, MDPrincipal InvestigatorPark Nicolette

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
Recent research and studies
clinicaltrials.govStudy
Proportional Open Ventilation (POV) Device and Its Efficacy in Managing Acute Respiratory Failure in COVID-19 Patients
2020. "Proportional Open Ventilation (POV) Device and Its Efficacy in Managing Acute Respiratory Failure in COVID-19 Patients". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT04581161.
~2 spots leftby Apr 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top